<DOC>
	<DOCNO>NCT00710424</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Sativex® compare placebo relieve pain due Diabetic Neuropathy .</brief_summary>
	<brief_title>A Study Sativex® Pain Relief Due Diabetic Neuropathy</brief_title>
	<detailed_description>This 15 week ( one week baseline fourteen week treatment period ) , multicentre , double blind , randomise , placebo control , parallel group study evaluate efficacy Sativex subject pain due diabetic neuropathy . Subjects screen determine eligibility complete seven-day baseline period . Subjects return centre assessment , randomisation dose introduction . Visits occur end week two , six , ten end study ( treatment week 14 ) early withdrew . A follow visit occur 28 day completion withdrawal . Subjects study give opportunity enrol open label extension study .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Willing able give inform consent . Male female , age 18 year . Ability ( investigator opinion ) willingness comply study requirement . Diagnosed Type 1 2 diabetes mellitus diagnose accord World Health Organisation ( WHO ) criterion . Diagnosed neuropathic pain due distal symmetrical diabetic neuropathy least six month duration , define NDS score least 4 , pain wholly relieve current therapy . The NDS score must attain least two different test parameter ankle jerk reflex . The last six daily diary 010 NRS pain score randomisation sum least 24 . Stable dose regular pain medication nonpharmacological therapy ( include TENS ) least 14 day prior screen visit willingness maintain throughout study . Agreement responsible authority ( applicable individual country ) , primary care physician , consultant , appropriate , notified participation study . Concomitant pain think investigator nature severity interfere assessment painful diabetic neuropathy . Uncontrolled diabetes HbA1c blood level 11 % Visit1 , Day B1 . Receiving prohibited medication unwilling stop comply duration study . Has use cannabinoid base medication within 60 day study entry unwilling abstain duration study . Has use cannabis within 30 day study entry unwilling abstain duration study . History schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . Known suspected history alcohol substance abuse . History epilepsy recurrent seizure . Known suspect hypersensitivity cannabinoids excipients IMP . Postural drop 20mmHg systolic blood pressure screen . Medical history gastroparesis . Evidence cardiomyopathy . Experienced myocardial infarction clinically relevant cardiac dysfunction within last 12 month cardiac disorder , opinion investigator would put subject risk clinically relevant arrhythmia myocardial infarction . QT interval ; &gt; 450 m ( male ) &gt; 470 m ( female ) Visit 1 . Secondary tertiary AV block sinus bradycardia ( HR &lt; 50bpm ) sinus tachycardia ( HR &gt; 110bpm ) Visit 1 . Diastolic blood pressure &lt; 50 mmHg &gt; 105 mmHg sit position rest five minute prior randomisation . Impaired renal function i.e. , creatinine clearance lower 50 ml/min Visit 1 . Significantly impaired hepatic function , Visit 1 , investigator 's opinion . Female subject child bear potential male subject whose partner child bear potential , unless willing ensure partner use effective contraception study three month thereafter . If female , pregnant lactating , plan pregnancy course study three month thereafter . Received IMP within 12 week Visit 1 . Any significant disease disorder , opinion investigator , may either put subject risk participation study , may influence result study , subject 's ability participate study . Following physical exam , subject abnormality , opinion investigator , would prevent subject safely participate study . Intention donate blood study . Intention travel internationally study . Previous randomisation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Pain</keyword>
	<keyword>diabetic neuropathy</keyword>
</DOC>